Masitinib Prostate Cancer Trial Gains FDA and E...

By HEOR Staff Writer

July 8, 2025

What is the latest on the masitinib prostate cancer trial, and how could it change treatment for metastatic castrate-resistant prostate cancer (mCRPC)? The masitinib prostate cancer trial recently received simultaneous authorizations from both ...
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical ...
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
Biosimilar Clinical Approach
Efficacy of Ultomiris Pediatric TMA Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...
Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies
The Case for Transparency in Peer Review: Enhancing Scientific Integrity and ...
Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges
Pluvicto Prostate Cancer Trial: Phase III Results